TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC). Galunisertib, an inhibitor of TGFβR1, was examined for its ability to enhance the efficacy of dinutuximab in combination with human ex vivo activated NK (aNK) cells against neuroblastoma. Experimental Design: TGFB1 and TGFBR1 mRNA expression was determined for 249 primary neuroblastoma tumors by microarray analysis. The ability of galunisertib to inhibit SMAD activity induced by neuroblastoma patient blood and bone marrow plasmas in neuroblastoma cells was tested. The impact of galunisertib on TGFβ1-induced inhibition of aNK cytotoxicity and ADCC in vitro and on anti-neuroblastoma activity in NOD-scid gamma (NSG) mice was determined. Results: Neuroblastomas express TGFB1 and TGFBR1 mRNA. Galunisertib suppressed SMAD activation in neuroblastoma cells induced by exogenous TGFβ1 or by patient blood and bone marrow plasma, and suppressed SMAD2 phosphorylation in human neuroblastoma cells growing in NSG mice. In NK cells treated in vitro with exogenous TGFβ1, galunisertib suppressed SMAD2 phosphorylation and restored the expression of DNAM-1, NKp30, and NKG2D cytotoxicity receptors and the TRAIL death ligand, the release of perforin and granzyme A, and the direct cytotoxicity and ADCC of aNK cells against neuroblastoma cells. Addition of galunisertib to adoptive cell therapy with aNK cells plus dinutuximab reduced tumor growth and increased survival of mice injected with two neuroblastoma cell lines or a patient-derived xenograft. Conclusions: Galunisertib suppresses activation of SMAD2 in neuroblastomas and aNK cells, restores NK cytotoxic mechanisms, and increases the efficacy of dinutuximab with aNK cells against neuroblastoma tumors. Clin Cancer Res; 23(3); 804–13. ©2016 AACR. See related commentary by Zenarruzabeitia et al., p. 615
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 17×
“Galunisertib decreases suppression of aNK cells by TGFb1 Having established that galunisertib reduces SMAD activity in neuroblastoma cells, we examined whether it might reduce the effects of TGFb1 on aNK cells.”
BackgroundInfluentialSelf-citationGranzymes in cancer and immunity
Cullen, S. P., Brunet, M., & Martin, S. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.206 · Cited by 391
Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151
Cited by
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
“…and Developmental Biology | www.frontiersin.org 9 April 2019 | Volume 7 | Article 60 showed promising clinical responses in neuroblastoma patients (Tran et al., 2017), galunisertib had no significant therapeutic effect in a phase II clinical study in recurrent glioblastoma patients (Brandes et…”
BackgroundBi, J., & Tian, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00760 · Cited by 325
Natural Killer–Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms
Neviani, P., Wise, P. M., Murtadha, M., Liu, C. W., Wu, C.-H., Jong, A. Y., Seeger, R. C., & Fabbri, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0779 · Cited by 324
Self-citationDisialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Nazha, B., Inal, C., & Owonikoko, T. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01000 · Cited by 324
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
Metadata
- Authors
- Tran, H. C., Wan, Z., Sheard, M. A., Sun, J., Jackson, J. R., Malvar, J., Xu, Y., Wang, L., Sposto, R., Kim, E. S., Asgharzadeh, S., & Seeger, R. C.
- Venue
- Clinical Cancer Research
- Published
- 2017-01-31
- Volume
- 23
- Issue
- 3
- Pages
- 804-813
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2531805832
- Cited by
- 132
- References
- 4
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1743
- The paper
- Tran, H. C., Wan, Z., Sheard, M. A., Sun, J., Jackson, J. R., Malvar, J., Xu, Y., Wang, L., Sposto, R., Kim, E. S., Asgharzadeh, S., & Seeger, R. C. (2017). TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.